市場調查報告書

局部性腎小球硬化(FSGS):市場洞察,流行病學,到2028年前的市場預測

Focal Segmental Glomerulosclerosis (FSGS) - Market Insights, Epidemiology, and Market Forecast-2028

出版商 DelveInsight Business Research LLP 商品編碼 905935
出版日期 內容資訊 英文 170 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
局部性腎小球硬化(FSGS):市場洞察,流行病學,到2028年前的市場預測 Focal Segmental Glomerulosclerosis (FSGS) - Market Insights, Epidemiology, and Market Forecast-2028
出版日期: 2019年08月01日內容資訊: 英文 170 Pages
簡介

本報告提供全球局部性腎小球硬化(FSGS)市場的相關調查,提供市場/疾病概要,流行病學,潛在的需求,競爭的主要產品,美國·德國·法國·義大利·西班牙·英國·日本的市場分析等資訊。

目錄

第1章 重要的洞察

第2章 局部性腎小球硬化(FSGS):市場概要

  • 2017年:市場佔有率(%)分佈
  • 2028年:市場佔有率(%)分佈

第3章 疾病概要:局部性腎小球硬化

  • 簡介
  • FSGS的分類
  • 徵兆及症狀
  • 組織病理學
  • 病因
  • 病因
  • 生物標記
  • FSGS的診斷
    • 鑑別診斷

第4章 流行病學及患者人口

  • 主要調查結果
  • 主要7個國家的整體患者數局部分節性腎小球硬化症
  • 國家智慧 - 局部分節性腎小球硬化症的流行病學
  • 美國
    • 假設及根據
    • 一般的病例
    • 性別病例
    • 各類型病例
    • 各年齡病例
  • 歐洲5個國家
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第5章 目前治療方法

  • 腎臟疾病:全球改善的成果 - KDIGO指南 - 成人的特發性FSGS

第6章 潛在的需求

第7章 主要競爭

  • Sparsentan: Retrophin
    • 藥的說明
    • 其他開發活動
    • 臨床開發
    • 安全性及有效性
    • 產品簡介
  • DMX-200: Dimerix
  • Voclosporin: Aurinia Pharmaceuticals
  • CXA-10: Complexa
  • Abatacept: Bristol-Myers Squibb
    • 產品說明
    • 其他開發活動
  • Bardoxolone methyl: Reata Pharmaceuticals/協和麒麟株式會社
  • Bleselumab: Astellas Pharma/協和麒麟株式會社
  • CCX140: Chemocentryx
  • PF-06730512: Pfizer

第8章 局部性腎小球硬化:7個主要的市場分析

  • 主要調查結果
  • 主要7個國家的局部性腎小球硬化的市場規模
  • 各國市場預測
  • 美國:市場預測
  • 美國的市場規模
    • 整體市場規模
    • 第1選擇療法:各市場規模
    • 第2選擇療法:各市場規模
  • 歐洲5個國家:市場預測
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第9章 市場成長要素

第10章 市場障礙

第11章 附錄

第12章 報告方法

第13章 DelveInsight的服務內容

第14章 免責聲明

第15章 關於DelveInsight

第16章 免責聲明

目錄
Product Code: DIMI0669

DelveInsight's 'Focal Segmental Glomerulosclerosis (FSGS)-Market Insights, Epidemiology, and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of Focal Segmental Glomerulosclerosis in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

The report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Focal Segmental Glomerulosclerosis from 2017 to 2028 segmented by seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate best of the opportunities and assess the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2028

Focal Segmental Glomerulosclerosis - Disease Understanding and Treatment Algorithm

The DelveInsight Focal Segmental Glomerulosclerosis market report gives a thorough understanding of FSGS by including details, such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Focal Segmental Glomerulosclerosis in the US, Europe, and Japan.

Focal Segmental Glomerulosclerosis Epidemiology

The Focal Segmental Glomerulosclerosis epidemiology division provide insights about historical and current patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report is segmented by Total Prevalent cases, Gender-specific cases, Type-specific cases [Primary, Secondary] and Age-specific cases [Children, Adult] in the 7MM.

According to DelveInsight, the total prevalent cases of Focal Segmental Glomerulosclerosis were 196,333 in 2017 in 7MM.

Focal Segmental Glomerulosclerosis Drug Chapters

This segment of the Focal Segmental Glomerulosclerosis report encloses the detailed analysis of marketed drugs and late-stage (Phase-II and III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Focal Segmental Glomerulosclerosis Market Outlook

The Focal Segmental Glomerulosclerosis market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.

This segment gives a thorough detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

Currently, there are no FDA-approved therapies for FSGS. The therapeutic market size of FSGS in the US is mainly accounted for by the off-label treatment options, such as non-immune therapy in conjunction with immunotherapy. The non-immune therapy includes angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers as the conservative treatment options. While, the immunotherapy includes, corticosteroids (Prednisone), calcineurin inhibitors (Cyclosporine and Tacrolimus), Mycophenolate Mofetil, and Biologics (rituximab), for those seriously ill patients. Kidney transplantation is the viable treatment options for children. In case of recurrence, plasmapheresis is the first-line treatment along with dialysis. Despite these available treatments, the management of FSGS remains a challenge due to the complex causes of disease and dense pathogenesis.

As per DelveInsight estimates, the market size of FSGS was found to be USD 333.36 Million in 2017. This market is further expected to grow during the forecasted period of 2019-2028 owing to the launch of upcoming therapies. Detailed chapters of the promising upcoming therapies, including Sparsentan (Retrophin), DMX-200 (Dimerix), Voclosporin (Aurinia Pharmaceuticals), CXA-10 (Complexa), Abatacept (Bristol-Myers Squibb), Bardoxolone methyl (Reata Pharmaceuticals/Kyowa Kirin), PF-06730512 (Pfizer), CCX140 (Chemocentryx) etc. are also provided in the report.

Focal Segmental Glomerulosclerosis Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017 to 2028. The analysis covers market uptake by drugs; patient uptake by therapies, and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs based on the market share and size, which again will be useful in investigating factors, vital in market uptake and in making financial and regulatory decisions.

Focal Segmental Glomerulosclerosis Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Focal Segmental Glomerulosclerosis Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Focal Segmental Glomerulosclerosis Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Focal Segmental Glomerulosclerosis market.
  • Organize sales and marketing efforts by identifying the best opportunities for Focal Segmental Glomerulosclerosis market.
  • To understand the future market competition in the Focal Segmental Glomerulosclerosis market.

Table of Contents

1. Key Insights

2. Focal Segmental Glomerulosclerosis (FSGS): Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of FSGS in 2017
  • 2.2. Market Share (%) Distribution of FSGS in 2028

3. Disease Overview: Focal Segmental Glomerulosclerosis

  • 3.1. Introduction
  • 3.2. Classification of FSGS
  • 3.3. Signs and Symptoms
  • 3.4. Histopathology
  • 3.5. Etiology
  • 3.6. Pathogenesis
  • 3.7. Biomarkers
  • 3.8. Diagnosis of FSGS
    • 3.8.1. Differential Diagnosis

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. 7MM Total Prevalent Patient Population of Focal Segmental Glomerulosclerosis
  • 4.3. Country Wise-Epidemiology of Focal Segmental Glomerulosclerosis
  • 4.4. United States
    • 4.4.1. Assumptions and Rationale
    • 4.4.2. Prevalent Cases of Focal Segmental Glomerulosclerosis in the United States
    • 4.4.3. Gender-Specific Cases of Focal Segmental Glomerulosclerosis in the US
    • 4.4.4. Type-Specific Cases of Focal Segmental Glomerulosclerosis in the US
    • 4.4.5. Age-Specific Cases of Focal Segmental Glomerulosclerosis in the US
  • 4.5. EU5
    • 4.5.1. Assumptions and Rationale
  • 4.6. Germany
    • 4.6.1. Prevalent Cases of Focal Segmental Glomerulosclerosis in Germany
    • 4.6.2. Gender-Specific Cases of Focal Segmental Glomerulosclerosis in Germany
    • 4.6.3. Type-Specific Cases of Focal Segmental Glomerulosclerosis in Germany
    • 4.6.4. Age-Specific Cases of Focal Segmental Glomerulosclerosis in Germany
  • 4.7. France
    • 4.7.1. Prevalent Cases of Focal Segmental Glomerulosclerosis in France
    • 4.7.2. Gender-Specific Cases of Focal Segmental Glomerulosclerosis in France
    • 4.7.3. Type-Specific Cases of Focal Segmental Glomerulosclerosis in France
    • 4.7.4. Age-Specific Cases of Focal Segmental Glomerulosclerosis in France
  • 4.8. Italy
    • 4.8.1. Prevalent Cases of Focal Segmental Glomerulosclerosis in Italy
    • 4.8.2. Gender-Specific Cases of Focal Segmental Glomerulosclerosis in Italy
    • 4.8.3. Type-Specific Cases of Focal Segmental Glomerulosclerosis in Italy
    • 4.8.4. Age-Specific Cases of Focal Segmental Glomerulosclerosis in Italy
  • 4.9. Spain
    • 4.9.1. Prevalent Cases of Focal Segmental Glomerulosclerosis in Spain
    • 4.9.2. Gender-Specific Cases of Focal Segmental Glomerulosclerosis in Spain
    • 4.9.3. Type-Specific Cases of Focal Segmental Glomerulosclerosis in Spain
    • 4.9.4. Age-Specific Cases of Focal Segmental Glomerulosclerosis in Spain
  • 4.10. United Kingdom
    • 4.10.1. Prevalent Cases of Focal Segmental Glomerulosclerosis in the United Kingdom
    • 4.10.2. Gender-Specific Cases of Focal Segmental Glomerulosclerosis in the United Kingdom
    • 4.10.3. Type-Specific Cases of Focal Segmental Glomerulosclerosis in the UK
    • 4.10.4. Age-Specific Cases of Focal Segmental Glomerulosclerosis in the UK
  • 4.11. Japan
    • 4.11.1. Assumptions and Rationale
    • 4.11.2. Prevalent Cases of Focal Segmental Glomerulosclerosis in Japan
    • 4.11.3. Gender-Specific Cases of Focal Segmental Glomerulosclerosis in Japan
    • 4.11.4. Type-Specific Cases of Focal Segmental Glomerulosclerosis in Japan
    • 4.11.5. Age-Specific Cases of Focal Segmental Glomerulosclerosis in Japan

5. Current Treatment Practices

  • 5.1. Kidney Disease: Improving Global Outcomes- KDIGO Guideline: Idiopathic FSGS in adults

6. Unmet Needs

7. Key cross competition

  • 7.1. Sparsentan: Retrophin
    • 7.1.1. Drug Description
    • 7.1.2. Other Developmental Activities
    • 7.1.3. Clinical Development
    • 7.1.4. Safety and Efficacy
    • 7.1.5. Product Profile
  • 7.2. DMX-200: Dimerix
    • 7.2.1. Drug Description
    • 7.2.2. Other Developmental Activities
    • 7.2.3. Clinical Development
    • 7.2.4. Safety and Efficacy
    • 7.2.5. Product Profile
  • 7.3. Voclosporin: Aurinia Pharmaceuticals
    • 7.3.1. Drug Description
    • 7.3.2. Other Developmental Activities
    • 7.3.3. Clinical Development
    • 7.3.4. Safety and Efficacy
    • 7.3.5. Product Profile
  • 7.4. CXA-10: Complexa
    • 7.4.1. Drug Description
    • 7.4.2. Other Developmental Activities
    • 7.4.3. Clinical Development
    • 7.4.4. Safety and Efficacy
    • 7.4.5. Product Profile
  • 7.5. Abatacept: Bristol-Myers Squibb
    • 7.5.1. Product Description
    • 7.5.2. Other Development Activities
    • 7.5.3. Clinical Development
    • 7.5.4. Product Profile
  • 7.6. Bardoxolone methyl: Reata Pharmaceuticals/Kyowa Kirin
    • 7.6.1. Drug Description
    • 7.6.2. Other Development Activities
    • 7.6.3. Clinical Development
    • 7.6.4. Safety and Efficacy
    • 7.6.5. Product Profile
  • 7.7. Bleselumab: Astellas Pharma/Kyowa Kirin
    • 7.7.1. Drug Description
    • 7.7.2. Clinical Development
    • 7.7.3. Product Profile
  • 7.8. CCX140: Chemocentryx
    • 7.8.1. Drug Description
    • 7.8.2. Other Developmental Activities
    • 7.8.3. Clinical Development
    • 7.8.4. Safety and Efficacy
    • 7.8.5. Product Profile
  • 7.9. PF-06730512: Pfizer
    • 7.9.1. Drug Description
    • 7.9.2. Clinical Development
    • 7.9.3. Product Profile

8. Focal Segmental Glomerulosclerosis: 7 Major Market Analysis

  • 8.1. Key Findings
  • 8.2. Market Size of Focal Segmental Glomerulosclerosis in 7MM
  • 8.3. Market Outlook by Country
  • 8.4. The United States: Market Outlook
  • 8.5. United States Market Size
    • 8.5.1. Total Market Size of Focal Segmental Glomerulosclerosis
    • 8.5.2. Market Size of Focal Segmental Glomerulosclerosis by First-line Therapies
    • 8.5.3. Market Size of Market Size of Focal Segmental Glomerulosclerosis by Second-line Therapies
  • 8.6. EU-5 Countries: Market Outlook
  • 8.7. Germany
    • 8.7.1. Total Market Size of Focal Segmental Glomerulosclerosis
    • 8.7.2. Market Size of Focal Segmental Glomerulosclerosis by First-line Therapies
    • 8.7.3. Market Size of Focal Segmental Glomerulosclerosis by Second-line Therapies
  • 8.8. France
    • 8.8.1. Total Market Size of Focal Segmental Glomerulosclerosis
    • 8.8.2. Market Size of Focal Segmental Glomerulosclerosis by First-line Therapies
    • 8.8.3. Market Size of Focal Segmental Glomerulosclerosis by Second-line Therapies
  • 8.9. Italy
    • 8.9.1. Total Market Size of Focal Segmental Glomerulosclerosis
    • 8.9.2. Market Size of Focal Segmental Glomerulosclerosis by First-line Therapies
    • 8.9.3. Market Size of Focal Segmental Glomerulosclerosis by Second-line Therapies
  • 8.10. Spain
    • 8.10.1. Total Market Size of Focal Segmental Glomerulosclerosis
    • 8.10.2. Market Size of Focal Segmental Glomerulosclerosis by First-line Therapies
    • 8.10.3. Market Size of Focal Segmental Glomerulosclerosis by Second-line Therapies
  • 8.11. United Kingdom
    • 8.11.1. Total Market Size of Focal Segmental Glomerulosclerosis
    • 8.11.2. Market Size of Focal Segmental Glomerulosclerosis by First-line Therapies
    • 8.11.3. Market Size of Focal Segmental Glomerulosclerosis by Second-line Therapies
  • 8.12. Japan: Market Outlook
  • 8.13. Total Market Size of Focal Segmental Glomerulosclerosis
  • 8.14. Market Size of Focal Segmental Glomerulosclerosis by First-line Therapies
  • 8.15. Market Size of Focal Segmental Glomerulosclerosis by Second-line Therapies

9. Market Drivers

10. Market Barriers

11. Appendix

12. Report Methodology

13. DelveInsight Capabilities

14. Disclaimer

15. About DelveInsight

16. Disclaimer

List of Tables

  • Table 1: Characteristic clinical and pathology features of the six forms of FSGS
  • Table 2: Causes of focal segmental glomerulosclerosis
  • Table 3: Genes related to FSGS or nephrotic syndrome
  • Table 4: Diagnostic protein biomarker candidates for FSGS
  • Table 5: Prognostic candidate biomarkers
  • Table 6: Differential diagnoses of FSGS
  • Table 7: Prevalent Patient Population of Focal Segmental Glomerulosclerosis in 7MM (2017-2028)
  • Table 8: Prevalent Cases of FSGS in the United States (2017-2028)
  • Table 9: Gender-specific cases of FSGS in the United States (2017-2028)
  • Table 10: Type-specific Cases of FSGS in the United States (2017-2028)
  • Table 11: Age-specific Cases of FSGS in the United States (2017-2028)
  • Table 12: Diagnosed Prevalent Cases of FSGS in Germany (2017-2028)
  • Table 13: Gender-specific cases of FSGS in Germany (2017-2028)
  • Table 14: Type-specific Cases of FSGS in Germany (2017-2028)
  • Table 15: Age-specific Cases of FSGS in Germany (2017-2028)
  • Table 16: Prevalent Cases of FSGS in France (2017-2028)
  • Table 17: Gender-specific cases of FSGS in France (2017-2028)
  • Table 18: Type-specific Cases of FSGS in France (2017-2028)
  • Table 19: Age-specific Cases of FSGS in France (2017-2028)
  • Table 20: Prevalent Cases of Focal Segmental Glomerulosclerosis in Italy (2017-2028)
  • Table 21: Gender-specific cases of FSGS in Italy (2017-2028)
  • Table 22: Type-specific Cases of FSGS in Italy (2017-2028)
  • Table 23: Age-specific Cases of FSGS in Italy (2017-2028)
  • Table 24: Diagnosed Prevalent Cases of FSGS in Spain (2017-2028)
  • Table 25: Gender-specific cases of FSGS in Spain (2017-2028)
  • Table 26: Type-specific Cases of FSGS in Spain (2017-2028)
  • Table 27: Age-specific Cases of FSGS in Spain (2017-2028)
  • Table 28: Prevalent Cases of FSGS in the United Kingdom (2017-2028)
  • Table 29: Gender-specific cases of FSGS in the United Kingdom (2017-2028)
  • Table 30: Type-specific Cases of FSGS in the UK (2017-2028)
  • Table 31: Age-specific Cases of FSGS in the UK (2017-2028)
  • Table 32: Prevalent Cases of FSGS in Japan (2017-2028)
  • Table 33: Gender-specific cases of FSGS in Japan (2017-2028)
  • Table 34: Type-specific Cases of FSGS in Japan (2017-2028)
  • Table 35: Age-specific Cases of FSGS in Japan (2017-2028)
  • Table 36: Pharmacologic therapies for FSGS
  • Table 37: KDIGO Definitions in Adult FSGS
  • Table 38: KDIGO Guideline: Idiopathic FSGS in adults
  • Table 39: Emerging Drugs Analysis
  • Table 40: Sparsentan, Clinical Trial Description, 2019
  • Table 41: DMX-200, Clinical Trial Description, 2019
  • Table 42: Voclosporin Clinical Trial Description, 2019
  • Table 43: CXA-10, Clinical Trial Description, 2019
  • Table 44: Abatacept, Clinical Trial Description, 2019
  • Table 45: Bardoxolone methyl (BARD), Clinical Trial Description, 2019
  • Table 46: Bleselumab, Clinical Trial Description, 2019
  • Table 47: CCX140-B, Clinical Trial Description, 2019
  • Table 48: PF-06730512, Clinical Trial Description, 2019
  • Table 49: 7 Major Market Size of Focal Segmental Glomerulosclerosis in USD Million (2017-2028)
  • Table 50: United States Market Size of FSGS, in USD Million (2017-2028)
  • Table 51: Market Size of FSGS by First-line Therapies in USD Million (2017-2028)
  • Table 52: Market Size of FSGS by Second-line Therapies in USD Million (2017-2028)
  • Table 53: Germany Market Size of FSGS, in USD Million (2017-2028)
  • Table 54: Market Size of FSGS by First-line Therapies in USD Million (2017-2028)
  • Table 55: Market Size of FSGS by Second-line Therapies in USD Million (2017-2028)
  • Table 56: France Market Size of FSGS, in USD Million (2017-2028)
  • Table 57: Market Size of FSGS by First-line Therapies in USD Million (2017-2028)
  • Table 58: Market Size of FSGS by Second-line Therapies in USD Million (2017-2028)
  • Table 59: Italy, Market Size of FSGS, in USD Million (2017-2028)
  • Table 60: Market Size of FSGS by First-line Therapies in USD Million (2017-2028)
  • Table 61: Market Size of FSGS by Second-line Therapies in USD Million (2017-2028)
  • Table 62: Spain, Market Size of FSGS, in USD Million (2017-2028)
  • Table 63: Market Size of FSGS by First-line Therapies in USD Million (2017-2028)
  • Table 64: Market Size of FSGS by Second-line Therapies in USD Million (2017-2028)
  • Table 65: UK Market Size of FSGS, in USD Million (2017-2028)
  • Table 66: Market Size of FSGS by First-line Therapies in USD Million (2017-2028)
  • Table 67: Market Size of FSGS by Second-line Therapies in USD Million (2017-2028)
  • Table 68: Japan, Market Size of FSGS, in USD Million (2017-2028)
  • Table 69: Market Size of FSGS by First-line Therapies in USD Million (2017-2028)
  • Table 70: Market Size of FSGS by Second-line Therapies in USD Million (2017-2028)

List of Figures

  • Figure 1: Focal Segmental Glomerulosclerosis
  • Figure 2: Common symptoms of Lupus
  • Figure 3: Histopathology of minimal change disease and focal segmental glomerulosclerosis
  • Figure 4: Pathogenesis of FSGS
  • Figure 5: Prevalent Patient Population of Focal Segmental Glomerulosclerosis in 7MM (2017-2028)
  • Figure 6: Prevalent Cases of FSGS in the United States (2017-2028)
  • Figure 7: Gender-specific Prevalent Cases of FSGS in the US (2017-2028)
  • Figure 8: Type-specific Diagnosed Prevalent Cases of FSGS in the US (2017-2028)
  • Figure 9: Age-specific Cases of FSGS in the US (2017-2028)
  • Figure 10: Prevalent Cases of FSGS in Germany (2017-2028)
  • Figure 11: Gender-specific of FSGS in Germany (2017-2028)
  • Figure 12: Type-specific Diagnosed Prevalent Cases of FSGS in Germany (2017-2028)
  • Figure 13: Age-specific Cases of FSGS in Germany (2017-2028)
  • Figure 14: Prevalent Cases of FSGS in France (2017-2028)
  • Figure 15: Gender-specific Cases of FSGS in France (2017-2028)
  • Figure 16: Type-specific Prevalent Cases of FSGS in France (2017-2028)
  • Figure 17: Age-specific Cases of FSGS in France (2017-2028)
  • Figure 18: Prevalent Cases of FSGS in Italy (2017-2028)
  • Figure 19: Gender-specific Cases of FSGS in Italy (2017-2028)
  • Figure 20: Type-specific Diagnosed Prevalent Cases of FSGS in Italy (2017-2028)
  • Figure 21: Age-specific Cases of FSGS in Italy (2017-2028)
  • Figure 22: Prevalent Cases of FSGS in Spain (2017-2028)
  • Figure 23: Gender-specific Cases of FSGS in Spain (2017-2028)
  • Figure 24: Type-specific Diagnosed Prevalent Cases of FSGS in Spain (2017-2028)
  • Figure 25: Age-specific Cases of FSGS in Spain (2017-2028)
  • Figure 26: Prevalent Cases of FSGS in the United Kingdom (2017-2028)
  • Figure 27: Gender-specific Cases of FSGS in the United Kingdom (2017-2028)
  • Figure 28: Type-specific Diagnosed Prevalent Cases of FSGS in the UK (2017-2028)
  • Figure 29: Age-specific Cases of FSGS in the UK (2017-2028)
  • Figure 30: Prevalent Cases of FSGS in Japan (2017-2028)
  • Figure 31: Gender-specific Cases of FSGS in Japan (2017-2028)
  • Figure 32: Type-specific Diagnosed Prevalent Cases of FSGS in Japan (2017-2028)
  • Figure 33: Age-specific Cases of FSGS in Japan (2017-2028)
  • Figure 34: Treatment algorithm
  • Figure 35: Unmet Needs
  • Figure 36: 7 Major Market Size of Focal Segmental Glomerulosclerosis in USD Million (2017-2028)
  • Figure 37: Market Size of FSGS in the United States, USD Millions (2017-2028)
  • Figure 38: Market Size of FSGS by First-line Therapies in USD Million (2017-2028)
  • Figure 39: Market Size of FSGS by Second-line Therapies in USD Million (2017-2028)
  • Figure 40: Market Size of FSGS in Germany, USD Millions (2017-2028)
  • Figure 41: Market Size of FSGS by First-line Therapies in USD Million (2017-2028)
  • Figure 42: Market Size of FSGS by Second-line Therapies in USD Million (2017-2028)
  • Figure 43: Market Size of FSGS in France, USD Millions (2017-2028)
  • Figure 44: Market Size of FSGS by First-line Therapies in USD Million (2017-2028)
  • Figure 45: Market Size of FSGS by Second-line Therapies in USD Million (2017-2028)
  • Figure 46: Market Size of FSGS in Italy, USD Millions (2017-2028)
  • Figure 47: Market Size of FSGS by First-line Therapies in USD Million (2017-2028)
  • Figure 48: Market Size of FSGS by Second-line Therapies in USD Million (2017-2028)
  • Figure 49: Market Size of FSGS in Spain, USD Millions (2017-2028)
  • Figure 50: Market Size of FSGS by First-line Therapies in USD Million (2017-2028)
  • Figure 51: Market Size of FSGS by Second-line Therapies in USD Million (2017-2028)
  • Figure 52: Market Size of FSGS in the UK, USD Millions (2017-2028)
  • Figure 53: Market Size of FSGS by First-line Therapies in USD Million (2017-2028)
  • Figure 54: Market Size of FSGS by Second-line Therapies in USD Million (2017-2028)
  • Figure 55: Market Size of FSGS in Japan, USD Millions (2017-2028)
  • Figure 56: Market Size of FSGS by First-line Therapies in USD Million (2017-2028)
  • Figure 57: Market Size of FSGS by Second-line Therapies in USD Million (2017-2028)
  • Figure 58: Market Drivers
  • Figure 59: Market Barriers
Back to Top